Terminology Service < Semantic Lookup Platform

All terms in NCIT

Label	Id	Description
Percent Change From Baseline in Sum of Longest Diameter	NCIT_C112371	[The most recently recorded sum of longest diameters minus the baseline sum of longest diameters divided by the baseline sum of longest diameters, multiplied by 100.]
Mitosis Inhibitor T 1101 Tosylate	NCIT_C151933	[The tosylate salt form of T-1101, an inhibitor of mitosis, with potential antineoplastic activity. Upon oral administration, T-1101 inhibits mitosis, through an as of yet not elucidated mechanism of action, which leads to decreased tumor cell proliferation.]
Antimitotic Agent	NCIT_C273	[An agent that inhibits tumor growth by interfering with mitotic processes or the assembly of the mitotic machinery.]
Serial Liquid Biopsy	NCIT_C151934	[Multiple liquid biopsies made over time.]
Liquid Biopsy	NCIT_C135727	[Sampling and analysis of non-solid biological material (primarily blood), usually to determine if cancer cells or circulating-free cancer DNA is present.]
Cancer Prevention Trial	NCIT_C15790	[Clinical trials that study ways of reducing the risk of getting cancer.]
Clinical Study by Targeted Disease or Condition	NCIT_C70819
Anti-CD19/CD20/CD22/CD30 CAR-T Cells	NCIT_C151935	[A preparation of human T-lymphocytes engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigens (TAAs) cluster of differentiation 19 (CD19), CD20, CD22 and CD30, with potential immunostimulating and antineoplastic activities. Upon administration, the anti-CD19/CD20/CD22/CD30 CAR-T cells target and bind to CD19, CD20, CD22 and CD30 expressed on the surface of certain tumor cells. This induces selective toxicity in tumor cells expressing these TAAs. The TAAs are overexpressed in certain hematologic malignancies.]
Testing	NCIT_C15336	[A procedure for critical evaluation.]
Autologous E6 T Cell Receptor Genetically-modified T Cells	NCIT_C151936	[A preparation of human autologous peripheral blood lymphocytes (PBLs) that have been genetically engineered to express a T-cell receptor (TCR) that specifically targets the viral oncoprotein human papillomavirus type 16 (HPV-16) E6, with potential antineoplastic activity. Upon administration, the HPV E6 TCR genetically-modified T-cells target and bind to HPV-16 E6-expressing tumor cells, which leads to specific cytotoxic T-lymphocyte (CTL)-mediated killing of HPV-16 E6-positive tumor cells. HPV-16 E6, a cell surface glycoprotein, plays a key role in the tumorigenesis of various HPV-associated tumors and is absent from healthy human tissues.]
Transplantation and Immune System	NCIT_C15792	[The interaction of a recipient's (patient's) immune system with an organ or tissue graft, or with the reactivity of donor-derived passenger leukocytes in the graft with the host's (patient's) body. (NCI/OSP)]
Funding Category	NCIT_C19335	[The specific subdivisions in a classification scheme of funding activities.]
Conduct Clinical Trials	NCIT_C15793	[Conduct clinical trials and develop new trial methodologies. Trials should be designed in order to rapidly develop new therapeutic strategies, optimize clinical efficacy and proper use of available modalities, define factors that affect the success of therapeutic strategies (including the role of resistance), and advance our understanding of disease pathogenesis and progression.]
Administrative Activity	NCIT_C49235	[Activities involved in the performance of executive, supervisory, or managerial duties.]
Cancer Therapy Evaluation Program	NCIT_C15794	[The program within the Division of Cancer Treatment and Diagnosis (DCTD) of the NCI which plans, assesses, and coordinates all aspects of clinical trials including extramural clinical research programs, internal resources, treatment methods and effectiveness, and compilation and exchange of data as it pertains to the development and evaluation of anticancer agents.]
Component of the Division of Cancer Treatment and Diagnosis	NCIT_C20165
Detection of Minimal Residual Disease	NCIT_C15795	[The discovery of a tumor or cancer after primary, potentially curative therapy.]
Developmental Diagnostic	NCIT_C15796	[Refers to diagnostic methods for evaluating developmental problems.]
Diagnostic Methods and Reagents	NCIT_C15797	[1A4; Basic Science Research (includes vaccine and chemotherapy development), Biomedical Research]
Diagnostics Research	NCIT_C15798